| Empres At Billings, Llc | |
|
3155 Avenue C, Billings, MT 59102-8109 | |
| (406) 656-8818 | |
| (406) 656-9552 |
| Full Name | Empres At Billings, Llc |
|---|---|
| Type | Facility |
| Speciality | Skilled Nursing Facility |
| Location | 3155 Avenue C, Billings, Montana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619402765 | NPI | - | NPPES |
| 522561 | Medicaid | MT | |
| 275140 | Other | MT | MEDICARE |
| Mailing Address | Practice Location Address |
|---|---|
| Empres At Billings, Llc 4601 Ne 77th Ave Ste 300, Vancouver, WA 98662-6736 Ph: (360) 892-6628 | Empres At Billings, Llc 3155 Avenue C, Billings, MT 59102-8109 Ph: (406) 656-8818 |
News Archive
The Center for Global Health Policy's "ScienceSpeaks" blog describes a panel discussion, which took place at last week's Society for International Development 2011 World Congress, that focused "on vertical and integrated approaches to global health [and] addressed the question of how best to achieve sustainable results in the field."
Elizabeth Hopkins, an aspiring physician and pre-medical student in the Charles E. Schmidt College of Science at Florida Atlantic University, has spent more than 640 hours shadowing Hilton Becker, M.D., a local plastic and reconstructive surgeon, and an affiliate professor in FAU's Charles E. Schmidt College of Medicine. Together, with Jeffrey Lind II, M.D., they authored a publication in the current issue of Plastic and Reconstructive Surgery Journal, which describes a revolutionary procedure developed by Becker that is an alternative to radical mastectomy.
Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a Phase 1b/2a study of its lead product candidate, CRLX101, in combination with Avastin, in metastatic renal cell carcinoma (mRCC) patients. The company also announced the completion of enrollment of its randomized Phase 2 study in advanced non-small cell lung cancer.
The cover for issue 1 of Oncotarget features Figure 2, "Results in clinical trials," published in "Drug resistant cells with very large proliferative potential grow exponentially in metastatic prostate cancer" by Blagoev, et al. which reported that most metastatic cancers develop drug resistance during treatment and continue to grow, driven by a subpopulation of cancer cells unresponsive to the therapy being administered.
...characterized by malaise, fatigue and depression, and often mistaken for poor performance, according to a study by Ann Barr, Ph.D., and Mary Barbe, Ph.D., at Temple University's College of Health Professions.
› Verified 6 days ago